2-methyl-1-(thiophen-3-yl)propan-1-one | 132387-69-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-1-(thiophen-3-yl)propan-1-one
• 英文别名: 2-(3-Thenoyl)propane；2-methyl-1-thiophen-3-ylpropan-1-one
• CAS: 132387-69-0
• 化学式: C₈H₁₀OS
• 分子量: 154.233
• InChiKey: RHKUMRZTWIUUSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-1-(thiophen-3-yl)propan-1-one 在 溶剂黄146 、 pyridinium hydrobromide perbromide 作用下， 反应 12.0h， 以97%的产率得到2-bromo-2-methyl-1-(thiophen-3-yl)propan-1-one
  参考文献：
  名称：

  可见光光氧化还原催化诱导的苯胺衍生物分子间CH键季烷基化反应

  摘要：

  用可见光催化方法报道了苯胺衍生物与α-溴代酮的分子间直接CH烷基化反应，以建立一个季碳中心。该反应以良好或优异的产率覆盖了各种官能团。观察到有利于胺基邻位的区域选择性，并用Fukui指数和光谱法研究。

  DOI：

  10.1021/acs.orglett.6b02179
• 作为产物：
  描述：

  3-乙酰基噻吩 、 碘甲烷 在 氢氧化钾 、 18-冠醚-6 作用下， 以 苯 为溶剂， 反应 76.0h， 以52%的产率得到2-methyl-1-(thiophen-3-yl)propan-1-one
  参考文献：
  名称：

  Goldberg, Yu.; Abele, E.; Shymanska, M., Synthetic Communications, 1990, vol. 20, # 18, p. 2741 - 2748

  摘要：

  DOI：

文献信息

• [EN] OXIMYL MACROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS MACROCYCLIQUES D'OXIMYLE
  申请人：ENANTA PHARM INC

  公开号：WO2009073713A1

  公开（公告）日：2009-06-11

  The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ( i ) which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及式I化合物，或其药用可接受的盐、酯或前药：(i)抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒(HCV) NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含前述化合物的药物组合物，用于给患有HCV感染的对象服用。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体HCV感染的方法。
• SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20200392130A1

  公开（公告）日：2020-12-17

  Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

  取代的吡唑并[4,3-b]吡啶作为GluN2B受体配体。这类化合物可用于GluN2B受体调节，以及用于治疗由GluN2B受体活性介导的疾病状态、疾病和症状的药物组合物和方法。
• Synthesis of [60]Fullerene-Fused Tetralones<i>via</i>Palladium- Catalyzed Ketone-Directed<i>sp</i>²CH Activation and<i>sp</i>³CH Functionalization
  作者：Dian-Bing Zhou、Guan-Wu Wang

  DOI：10.1002/adsc.201501112

  日期：2016.5.19

  The palladium‐catalyzed ketone‐directed dual sp2 CH activation and sp3 CH functionalization has been applied for fullerene functionalization for the first time. The sec‐alkyl aryl ketones have been exploited to react with [60]fullerene (C60) to provide the novel and scarce C60‐fused tetralones. The combined use of a highly active cationic palladium(II) catalyst and trifluoromethanesulfonic acid is

  钯催化酮定向双SP 2 ç  ħ活化和SP 3 Ç  ħ官能已申请首次富勒烯官能化。的秒-烷基芳基酮已被利用来与[60]富勒烯（C反应60），以提供新颖的和稀缺Ç 60 -融合四氢萘酮。高活性阳离子钯（II）催化剂和三氟甲磺酸的组合使用对于提高反应收率至关重要。已经提出了导致观察到的产物的合理的反应机理，并且还研究了富勒烯产物的电化学。
• Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors
  申请人：Niu Deqiang

  公开号：US20070299078A1

  公开（公告）日：2007-12-27

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及化合物，包括式I的化合物，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒药剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Quinoxalinyl tripeptide hepatitis C virus inhibitors
  申请人：Gai Yonghua

  公开号：US20080032936A1

  公开（公告）日：2008-02-07

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I的化合物，或其药用可接受的盐、酯或前药，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，同时也可用作抗病毒药物。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者投与含本发明化合物的药物组合物来治疗HCV感染的方法。